Title | PKCλ/ι inhibition activates an ULK2-mediated interferon response to repress tumorigenesis. |
Publication Type | Journal Article |
Year of Publication | 2021 |
Authors | Linares JF, Zhang X, Martinez-Ordoñez A, Duran A, Kinoshita H, Kasashima H, Nakanishi N, Nakanishi Y, Carelli R, Cappelli L, Arias E, Yashiro M, Ohira M, Patel S, Inghirami G, Loda M, Cuervo AMaria, Diaz-Meco MT, Moscat J |
Journal | Mol Cell |
Date Published | 2021 Sep 18 |
ISSN | 1097-4164 |
Abstract | The interferon (IFN) pathway is critical for cytotoxic T cell activation, which is central to tumor immunosurveillance and successful immunotherapy. We demonstrate here that PKCλ/ι inactivation results in the hyper-stimulation of the IFN cascade and the enhanced recruitment of CD8 T cells that impaired the growth of intestinal tumors. PKCλ/ι directly phosphorylates and represses the activity of ULK2, promoting its degradation through an endosomal microautophagy-driven ubiquitin-dependent mechanism. Loss of PKCλ/ι results in increased levels of enzymatically active ULK2, which, by direct phosphorylation, activates TBK1 to foster the activation of the STING-mediated IFN response. PKCλ/ι inactivation also triggers autophagy, which prevents STING degradation by chaperone-mediated autophagy. Thus, PKCλ/ι is a hub regulating the IFN pathway and three autophagic mechanisms that serve to maintain its homeostatic control. Importantly, single-cell multiplex imaging and bioinformatics analysis demonstrated that low PKCλ/ι levels correlate with enhanced IFN signaling and good prognosis in colorectal cancer patients. |
DOI | 10.1016/j.molcel.2021.08.039 |
Alternate Journal | Mol Cell |
PubMed ID | 34560002 |
Grant List | R01 CA218254 / CA / NCI NIH HHS / United States |
Related Faculty:
Giorgio Inghirami, M.D. Juan Francisco Linares Rodriguez, Ph.D. Maria Diaz-Meco Conde, Ph.D. Massimo Loda, M.D. Sanjay Patel, M.D., MPH